NCT03090165: Ribociclib and Bicalutamide in AR+ TNBC

NCT03090165
Breast Cancer Type: Triple Negative
Hormone Mutations: AR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with active central nervous system (CNS) metastasis- see trial for details
https://ClinicalTrials.gov/show/NCT03090165

Comments are closed.

Up ↑